SCHEMBL17045283

SCHEMBL17045283

CNC(=O)OC[C@@H](N)Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.51
EPHX1 P07099 1/20 0.48
CYP1A2 P05177 1/20 0.48
SCN4A P35499 2/20 0.48
ALPI P09923 1/20 0.46
PKM P14618 1/20 0.46
PTGS1 P23219 1/20 0.46
XIAP P98170 1/20 0.46
SLC7A5 Q01650 1/20 0.46
TACR1 P25103 1/20 0.46
LAP3 P28838 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045285 1.00 MMP2 (0.51) MMP2EPHX1CYP1A2SCN4AALPI
SCHEMBL11947651 1.00 MMP2 (0.51) MMP2EPHX1CYP1A2SCN4AALPI
SCHEMBL17045249 0.86 MMP2 (0.50) MMP2EPHX1SCN4AALPIPKM
SCHEMBL17045247 0.86 MMP2 (0.50) MMP2EPHX1SCN4AALPIPKM
SCHEMBL11947649 0.86 MMP2 (0.50) MMP2EPHX1SCN4AALPIPKM
SCHEMBL17045270 0.86 ATM (0.41) MMP2CYP1A2SCN4ATACR1
SCHEMBL17045267 0.86 ATM (0.41) MMP2CYP1A2SCN4ATACR1
SCHEMBL11947639 0.86 ATM (0.41) MMP2CYP1A2SCN4ATACR1
SCHEMBL17045269 0.85 SLC6A4 (0.51) CYP1A2SCN4A
SCHEMBL11947660 0.85 MMP2 (0.49) MMP2EPHX1SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255921-A1 COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND CELLIONBIOMED INC. (KR) 2023-08-17 US disclosed
EP-4223291-A1 COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND Cellionbiomed Inc. (KR) 2023-08-09 EP disclosed
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US disclosed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US disclosed
US-10888542-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-01-12 US disclosed
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2020-02-13 US disclosed
EP-3110792-B1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2019-09-04 EP disclosed
US-20190247356-A1 Aminocarbonylcarbamate Compounds SK BIOPHARMACEUTICALS CO., LTD. 2019-08-15 US disclosed
US-10314808-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2019-06-11 US disclosed
US-20180085337-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2018-03-29 US disclosed
US-9833432-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-12-05 US disclosed
EP-3110792-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK Biopharmaceuticals Co., Ltd. (KR) 2017-01-04 EP disclosed
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. 2016-10-20 US disclosed
US-9403761-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-08-02 US disclosed
WO-2015130121-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 WO disclosed
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255921-A1 COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND KCNA3, KCNN3, KCNMA1 MMP2 4506/4885EPHX1 1970/4885CYP1A2 3780/4885
US-20190247356-A1 Aminocarbonylcarbamate Compounds SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-10888542-B2 Aminocarbonylcarbamate compounds SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20180085337-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885
US-10314808-B2 Aminocarbonylcarbamate compounds SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.